Newly Published Study Demonstrates Clinical Utility of Daxor’s Blood Volume (BVA-100®) Diagnostic in the Assessment of Postural Tachycardia Syndrome (POTS)
29 avr. 2021 08h31 HE
|
Daxor Corporation
NEW YORK, April 29, 2021 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement technology, today announces new data demonstrating the clinical utility...
DAXOR CORPORATION TO PARTICIPATE IN BENZINGA BIOTECH SMALL CAP CONFERENCE
18 mars 2021 08h30 HE
|
Daxor Corporation
NEW YORK, March 18, 2021 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, announces today that President and CEO Michael Feldschuh will...
Daxor to Participate in the Maxim Group 2021 Emerging Growth Virtual Conference
16 mars 2021 08h30 HE
|
Daxor Corporation
NEW YORK, March 16, 2021 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, announces today that President and CEO Michael Feldschuh will...
DAXOR CORPORATION ANNOUNCES NOVEL FLUORESCENT TRACER AND PHASE-TWO US AIR FORCE CONTRACT AWARD OF $750,000 FOR POINT-OF-CARE OPTICAL BLOOD VOLUME ANALYZER
15 mars 2021 08h30 HE
|
Daxor Corporation
BREAKTHROUGH PATENT-PENDING TRACER DEVELOPED FOR BROAD USE NEW YORK, March 15, 2021 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement...
Daxor to Present at the H.C. Wainwright Global Life Sciences Conference
04 mars 2021 08h30 HE
|
Daxor Corporation
NEW YORK, March 04, 2021 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, announces today that President and CEO Michael Feldschuh will...
Daxor Corporation Announces $0.48 Per Share NAV Increase and Files Annual Report for Fiscal 2020
26 févr. 2021 08h30 HE
|
Daxor Corporation
Revenues of Operating Division Increase by 50.4% NEW YORK, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR) The global leader in blood volume technology today filed its Annual...
DAXOR CORPORATION RECEIVES ISO 13485 QUALITY MANAGEMENT SYSTEM CERTIFICATION FOR THE BLOOD VOLUME ANALYZER (BVA-100®)
19 févr. 2021 08h30 HE
|
Daxor Corporation
Important Milestone for International Distribution NEW YORK, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement technology, announces...
DAXOR CORPORATION AWARDED GRANT FROM THE CENTER FOR ADVANCING POINT OF CARE TECHNOLOGIES (CAPCAT) TO DEVELOP A POINT-OF-CARE BLOOD VOLUME ANALYZER
05 févr. 2021 08h30 HE
|
Daxor Corporation
NEW YORK, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement technology, announces today that it has been awarded a grant from the...
New Research Demonstrates the Clinical Utility with Daxor’s Blood Volume Analyzer (BVA-100®) in Critical Care
04 févr. 2021 08h30 HE
|
Daxor Corporation
Study Presented At the Society for Critical Care Medicine (SCCM) 50th Congress NEW YORK, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR) the global leader in blood volume...
DAXOR CORPORATION TO EXHIBIT AT THE SOCIETY FOR CRITICAL CARE MEDICINE 50TH CONGRESS VIRTUAL EVENT
26 janv. 2021 08h30 HE
|
Daxor Corporation
NEW DATA SCHEDULED FOR PRESENTATION ON DAXOR’S BVA-100® BLOOD TEST NEW YORK, Jan. 26, 2021 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement...